These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 9232213

  • 21. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
    Zwanzger P, Baghai TC, Schuele C, Ströhle A, Padberg F, Kathmann N, Schwarz M, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
    [Abstract] [Full Text] [Related]

  • 22. Effect of CCK-4 on a 35% carbon dioxide challenge in healthy volunteers.
    Pols H, Griez E, Bourin M, Schruers K.
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Nov; 23(8):1345-50. PubMed ID: 10631762
    [Abstract] [Full Text] [Related]

  • 23. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
    Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F, Yehuda R.
    Biol Psychiatry; 2000 Jan 15; 47(2):107-11. PubMed ID: 10664826
    [Abstract] [Full Text] [Related]

  • 24. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
    Schunck T, Mathis A, Erb G, Namer IJ, Hode Y, Demazières A, Luthringer R.
    J Psychopharmacol; 2011 Jan 15; 25(1):52-9. PubMed ID: 20498136
    [Abstract] [Full Text] [Related]

  • 25. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
    Wiedemann K, Jahn H, Yassouridis A, Kellner M.
    Arch Gen Psychiatry; 2001 Apr 15; 58(4):371-7. PubMed ID: 11296098
    [Abstract] [Full Text] [Related]

  • 26. Ventilatory response to cholecystokinin tetrapeptide in anaesthetized dogs.
    Bates JH, Bradwejn J.
    Neuroreport; 1995 Dec 15; 6(18):2513-7. PubMed ID: 8741752
    [Abstract] [Full Text] [Related]

  • 27. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
    Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H.
    Arch Gen Psychiatry; 1994 Jun 15; 51(6):486-93. PubMed ID: 8192551
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety.
    Schunck T, Erb G, Mathis A, Gilles C, Namer IJ, Hode Y, Demaziere A, Luthringer R, Macher JP.
    Neuroimage; 2006 Jul 01; 31(3):1197-208. PubMed ID: 16600640
    [Abstract] [Full Text] [Related]

  • 30. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
    Goettel M, Fuertig R, Mack SR, Just S, Sharma V, Wunder A, den Boer J.
    CNS Drugs; 2023 Dec 01; 37(12):1099-1109. PubMed ID: 38019356
    [Abstract] [Full Text] [Related]

  • 31. Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers.
    Aluoja A, Shlik J, Vasar V, Kingisepp PH, Jagomägi K, Vasar E, Bradwejn J.
    Psychiatry Res; 1997 Jan 15; 66(1):59-67. PubMed ID: 9061804
    [Abstract] [Full Text] [Related]

  • 32. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD, Slate SO, Geraci M, Uhde TW.
    Anxiety; 1997 Jan 15; 1(6):258-67. PubMed ID: 9160584
    [Abstract] [Full Text] [Related]

  • 33. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
    Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K.
    Psychopharmacology (Berl); 2005 Apr 15; 179(1):310-5. PubMed ID: 15821951
    [Abstract] [Full Text] [Related]

  • 34. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
    Kellner M, Yassouridis A, Jahn H, Wiedemann K.
    Psychopharmacology (Berl); 1997 Sep 15; 133(1):55-61. PubMed ID: 9335081
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.
    Koszycki D, Cox BJ, Bradwejn J.
    Am J Psychiatry; 1993 Dec 15; 150(12):1881-3. PubMed ID: 8238648
    [Abstract] [Full Text] [Related]

  • 37. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
    Le Mellédo JM, Bradwejn J, Koszycki D, Bichet DG, Bellavance F.
    Biol Psychiatry; 1998 Sep 01; 44(5):364-6. PubMed ID: 9755359
    [Abstract] [Full Text] [Related]

  • 38. Acute cholecystokinin effects on event-related potentials in healthy volunteers.
    Knott VJ, Mahoney C, Gunnarsson T, Bradwejn J, Shlik J.
    Hum Psychopharmacol; 2002 Aug 01; 17(6):285-91. PubMed ID: 12404673
    [Abstract] [Full Text] [Related]

  • 39. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
    Maron E, Tõru I, Vasar V, Shlik J.
    J Psychopharmacol; 2004 Jun 01; 18(2):194-9. PubMed ID: 15260907
    [Abstract] [Full Text] [Related]

  • 40. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
    Demiralay C, Jahn H, Kellner M, Yassouridis A, Wiedemann K.
    World J Biol Psychiatry; 2012 Oct 01; 13(7):526-34. PubMed ID: 22111662
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.